Open Orphan deal to generate ‘significant revenue’ for Venn Life Sciences

New contract with Japanese company Carna Bioscience follows close collaboration on drug development planning and pre-clinical activities

Open Orphan executive chairman Cathal Friel.

Open Orphan executive chairman Cathal Friel.

Dublin-listed pharmaceutical services company Open Orphan has signed a new contract with a Japanese group which it expects will generate “significant revenue” for subsidiary Venn Life Sciences over the next year.

Open Orphan, a European-focused, rare and orphan drug consulting services platform, said on Tuesday the contract with Carna Bioscience was for a first in human clinical pharmacology trials.

Please subscribe or sign in to continue reading.
only €1 first month

Insightful opinion is just a away.